Industry Dialogue on PRIP Strengthens Pharma Ecosystem

17 Mar 2025 CW Team

The Department of Pharmaceuticals, Government of India, convened an Industry Dialogue in Mumbai to discuss the Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) Scheme. The event brought together industry leaders, research institutions, and pharmaceutical associations, including representatives from the Indian Council for Medical Research (ICMR), the Council of Scientific and Industrial Research (CSIR), and the National Institute of Pharmaceutical Education and Research (NIPERs). Discussions focused on strengthening industry-academia linkages, fostering collaboration, and leveraging government initiatives to accelerate R&D and commercialise innovative solutions in the pharmaceutical and medical technology sectors.

Government Initiatives to Boost Innovation In addition to the PRIP Scheme, the dialogue highlighted key government initiatives aimed at promoting research and innovation in the sector:

ICMR’s PATENT MITRA, MEDTECH MITRA, and INTENT programs – Supporting patent filing, guiding the innovation journey, and facilitating clinical trials. CSIR’s Innovation Complex in Mumbai – Bridging the gap between research institutions and industry through translational research. Industry Leaders Call for Stronger Policy and Investment Support Prominent industry figures voiced their insights on the challenges and opportunities in Pharma-MedTech R&D:

Dr Sharvil Patel, Vice President, Indian Pharmaceutical Association (IPA) – Stressed the importance of industry-driven innovation, regulatory support, and increased investments in emerging pharmaceutical technologies. Mr Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI) – Highlighted the need for a conducive policy environment to encourage greater industry participation in R&D. Mr Bharat Shah, National President, Indian Drug Manufacturers' Association (IDMA) – Addressed the challenges MSMEs face in adopting research-led growth strategies and welcomed the PRIP scheme’s role in catalysing innovation. Mr Veeraal Gandhi, Vice President, Association of Diagnostics Manufacturers India (ADMI) – Spoke on India’s potential to lead in diagnostic technologies, particularly in point-of-care innovations, to enhance advanced healthcare solutions. Government’s Vision for Future-Ready Healthcare Solutions Shri Amit Agrawal, Secretary, Department of Pharmaceuticals, underscored the importance of futuristic products and affordable healthcare solutions as key drivers of India’s global leadership in pharmaceuticals and MedTech. He emphasised that:

Data-driven markets will play a transformative role in shaping Pharma-MedTech R&D. India, with its highly diverse gene pool and one-sixth of the world’s population, has a unique advantage in developing personalised and precision medicines. The PRIP Scheme aims to support innovative, cost-effective, and affordable healthcare solutions that will strengthen domestic and global healthcare ecosystems. Breakout Sessions and Stakeholder Engagement The event featured breakout sessions, where industry representatives and stakeholders provided insights on emerging R&D trends, regulatory pathways, and funding opportunities. Discussions covered:

Enhancing industry-academia collaboration to drive research and innovation. Streamlining regulatory pathways to facilitate faster commercialisation of new technologies. Scaling up research initiatives to fuel sectoral growth. Stakeholders were encouraged to submit their feedback and project details via the Expression of Interest (EoI) on the Department of Pharmaceuticals website, open until April 7, 2025. This process aims to refine the PRIP Scheme’s implementation to better align with industry needs.

The Industry Dialogue in Mumbai concluded on a highly optimistic note, with participants reaffirming their commitment to fostering an innovation-driven ecosystem in the Pharma-MedTech sector. The event reinforced government-industry collaboration, paving the way for transformative advancements in healthcare, pharmaceuticals, and medical technology.

Real Estate

06 Apr 2026

MAIA Estates Launches ‘The Seven’ in South Bengaluru

MAIA Estates has recently announced the launch of ‘The Seven’, a premium residential development in Basavanagudi, South Bengaluru. The project comprises twin towers across a 3.67-acre site, offering 128 exclusive 4 BHK+ residences spread over 36 storeys, with a total saleable area of around 6,00,000 sq ft. Completion is targeted by 2029.Developed under a joint development agreement, the project is backed by Rs 1.2 billion in institutional funding from Arnya Real Estate Fund – Debt. The launch marks the company’s entry into South Bengaluru, a micro-market characterised by limited premiu..

Hindustan Zinc Reports Record FY26 Production

Hindustan Zinc Limited recently reported its production performance for the fourth quarter and financial year ended March 31, 2026, recording its highest-ever output across key segments.Mined metal production reached a record 315 kt in 4QFY26 and 1,114 kt for FY26, supported by higher ore output and improved grades. Refined metal output stood at 282 kt for the quarter, driven by capacity enhancements at Chanderiya and Dariba, alongside improved operational efficiency.Refined zinc production rose to 851 kt in FY26, up 3 per cent year-on-year, supported by debottlenecking projects and expanded r..

CFI Appoints New National Council for FY27 and FY28

The Construction Federation of India (CFI) has announced its newly elected National Council and office bearers for a two-year term covering FY27 and FY28. M. V. Satish, Advisor to CMD and Lead Ambassador for Middle East, L&T, has been elected President; Priti Patel, Chief Strategy & Growth Officer, Tata Projects, has been appointed Vice President; and Ajit Bhate, Managing Director, Precast India Infrastructures, has taken charge as Treasurer.The newly formed National Council brings together senior leaders from major EPC and infrastructure companies, reflecting CFI’s continued focus o..